Latest Developments in Engineered Skeletal Muscle Tissues for Drug Discovery and Development

dc.contributor.author Ostrovidov, Serge
dc.contributor.author Ramalingam, Murugan
dc.contributor.author Bae, Hojae
dc.contributor.author Orive, Gorka
dc.contributor.author Fujie, Toshinori
dc.contributor.author Shi, Xuetao
dc.contributor.author Kaji, Hirokazu
dc.contributor.other 01. Atılım University
dc.date.accessioned 2024-07-05T15:24:08Z
dc.date.available 2024-07-05T15:24:08Z
dc.date.issued 2023
dc.description Fujie, Toshinori/0000-0003-1417-8670; Kaji, Hirokazu/0000-0003-2566-4172; Ramalingam, Murugan/0000-0001-6498-9792; ostrovidov, serge/0000-0002-4189-8086; bae, hojae/0000-0003-3057-4999 en_US
dc.description.abstract IntroductionWith the advances in skeletal muscle tissue engineering, new platforms have arisen with important applications in biology studies, disease modeling, and drug testing. Current developments highlight the quest for engineering skeletal muscle tissues with higher complexity . These new human skeletal muscle tissue models will be powerful tools for drug discovery and development and disease modeling.Areas coveredThe authors review the latest advances in in vitro models of engineered skeletal muscle tissues used for testing drugs with a focus on the use of four main cell culture techniques: Cell cultures in well plates, in microfluidics, in organoids, and in bioprinted constructs. Additional information is provided on the satellite cell niche.Expert opinionIn recent years, more sophisticated in vitro models of skeletal muscle tissues have been fabricated. Important developments have been made in stem cell research and in the engineering of human skeletal muscle tissue. Some platforms have already started to be used for drug testing, notably those based on the parameters of hypertrophy/atrophy and the contractibility of myotubes. More developments are expected through the use of multicellular types and multi-materials as matrices . The validation and use of these models in drug testing should now increase. en_US
dc.description.sponsorship Japan Society for the Promotion of Science (JSPS) KAKENHI [22K18936, 21K04852]; AMED [JP21gm1310001]; JST Adaptable and Seamless Technology Transfer Program through Target-driven RD [JPMJTM22BD, JPMJTM22BE]; CASIO SCIENCE PROMOTION FOUNDATION; Research Center for Biomedical Engineering at Tokyo Medical and Dental University, Japan; Spanish Ministry of Economy, Industry, and Competitiveness [PID2019-106094RB-I00/AEI]; Grants-in-Aid for Scientific Research [22K18936] Funding Source: KAKEN en_US
dc.description.sponsorship This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Numbers 22K18936 and 21K04852); AMED (Grant Number JP21gm1310001); JST Adaptable and Seamless Technology Transfer Program through Target-driven R&D (Grant Numbers JPMJTM22BD and JPMJTM22BE); CASIO SCIENCE PROMOTION FOUNDATION, and the Research Center for Biomedical Engineering at Tokyo Medical and Dental University, Japan. Furthermore, G Orive thanks the Spanish Ministry of Economy, Industry, and Competitiveness (PID2019-106094RB-I00/AEI/10.13039/501100011033) for their support. en_US
dc.identifier.doi 10.1080/17460441.2023.2160438
dc.identifier.issn 1746-0441
dc.identifier.issn 1746-045X
dc.identifier.scopus 2-s2.0-85145288436
dc.identifier.uri https://doi.org/10.1080/17460441.2023.2160438
dc.identifier.uri https://hdl.handle.net/20.500.14411/2397
dc.language.iso en en_US
dc.publisher Taylor & Francis Ltd en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Bioprinting en_US
dc.subject drug development en_US
dc.subject drug evaluation en_US
dc.subject microfluidics en_US
dc.subject muscle skeletal en_US
dc.subject organoids en_US
dc.subject stem cells en_US
dc.title Latest Developments in Engineered Skeletal Muscle Tissues for Drug Discovery and Development en_US
dc.type Review en_US
dspace.entity.type Publication
gdc.author.id Fujie, Toshinori/0000-0003-1417-8670
gdc.author.id Kaji, Hirokazu/0000-0003-2566-4172
gdc.author.id Ramalingam, Murugan/0000-0001-6498-9792
gdc.author.id ostrovidov, serge/0000-0002-4189-8086
gdc.author.id bae, hojae/0000-0003-3057-4999
gdc.author.scopusid 6602776344
gdc.author.scopusid 59176479500
gdc.author.scopusid 35799555800
gdc.author.scopusid 6602772615
gdc.author.scopusid 12801720000
gdc.author.scopusid 55617444400
gdc.author.scopusid 55617444400
gdc.author.wosid Shi, Xuetao/D-5180-2012
gdc.author.wosid Fujie, Toshinori/O-1493-2018
gdc.author.wosid Kaji, Hirokazu/T-2219-2019
gdc.author.wosid Ramalingam, Murugan/AAV-1702-2020
gdc.coar.access metadata only access
gdc.coar.type text::review
gdc.description.department Atılım University en_US
gdc.description.departmenttemp [Ostrovidov, Serge; Kaji, Hirokazu] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn IBB, Dept Biomech, Tokyo, Japan; [Ramalingam, Murugan] Dankook Univ, Inst Tissue Regenerat Engn, Cheonan, South Korea; [Ramalingam, Murugan] Dankook Univ, PLUS NBM Global Res Ctr, Dept Nanobiomed Sci, BK21,Regenerat Med Res Ctr, Cheonan, South Korea; [Ramalingam, Murugan] Chengdu Univ, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China; [Bae, Hojae] Konkuk Univ, KU Convergence Sci & Technol Inst, Dept Stem Cell & Regenerat Biotechnol, Hwayang dong,Kwangjin Gu, Seoul, South Korea; [Orive, Gorka] Univ Basque Country UPV, Vitoria-gasteiz, Spain; [Orive, Gorka] Univ Basque Country UPV, Sch Pharm, Lab Pharmaceut, NanoBioCel Grp, Vitoria, Spain; [Orive, Gorka] Biomed Res Networking Ctr Bioengn, Biomat & Nanomed CIBER BBN, Vitoria, Spain; [Fujie, Toshinori] Tokyo Inst Technol, Dept Life Sci & Technol, Yokohama, Japan; [Shi, Xuetao] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou, Guangdong, Peoples R China; [Ramalingam, Murugan] Dankook Univ, Mechanobiol Dent Med Res Ctr, Cheonan, South Korea; [Ramalingam, Murugan] Atilim Univ, Dept Met & Mat Engn, Ankara, Turkey en_US
gdc.description.endpage 63 en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Diğer en_US
gdc.description.scopusquality Q1
gdc.description.startpage 47 en_US
gdc.description.volume 18 en_US
gdc.description.wosquality Q1
gdc.identifier.openalex W4313423315
gdc.identifier.pmid 36535280
gdc.identifier.wos WOS:000903993900001
gdc.openalex.fwci 0.52
gdc.openalex.normalizedpercentile 0.46
gdc.opencitations.count 5
gdc.plumx.mendeley 16
gdc.plumx.pubmedcites 2
gdc.plumx.scopuscites 7
gdc.scopus.citedcount 7
gdc.wos.citedcount 6
relation.isOrgUnitOfPublication 50be38c5-40c4-4d5f-b8e6-463e9514c6dd
relation.isOrgUnitOfPublication.latestForDiscovery 50be38c5-40c4-4d5f-b8e6-463e9514c6dd

Files

Collections